NASDAQ$VYNE
VYNE Therapeutics INC · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Reported financial results for the second quarter of 2024 and provided a business update.
VYNE Therapeutics reported second quarter 2024 financial results, highlighting the initiation of a Phase 2b trial of VYN201 in nonsegmental vitiligo and a Phase 1a trial of VYN202. The company's cash position is expected to fund key clinical milestones through the end of 2025.
- Initiated Phase 2b trial of VYN201 in nonsegmental vitiligo, with top-line results expected in mid-2025.
- Phase 1a SAD/MAD trial of VYN202 progressing, with data expected in Q3 and Q4 2024, respectively.
- Cash, cash equivalents, restricted cash and marketable securities totaled $78.1 million as of June 30, 2024.
- Balance sheet is expected to fund key clinical milestones for VYN201 and VYN202 through the end of 2025.
Headline financials
Revenue & EPS history
VYNE · Revenue · Quarterly
$198K
Revenue by segment
VYNE · $86K total across 1 segment · Q1 2026
- Royalty revenues$86K—100.0%
Forward guidance
VYNE expects to report top-line data from the single ascending dose portion of the Phase 1a trial of VYN202 this quarter, followed by results from the multiple ascending dose portion in the fourth quarter. VYNE remains on track to report top-line data from its Phase 2b clinical trial for VYN201 in subjects with nonsegmental vitiligo in the middle of next year.
Tailwinds
- Top-line data from VYN202 Phase 1a SAD portion expected in Q3 2024.
- Top-line data from VYN202 Phase 1a MAD portion expected in Q4 2024.
- Top-line data from VYN201 Phase 2b trial expected in mid-2025.
- Plan to advance VYN202 into two Phase 1b proof-of-concept trials.
- Top-line readouts from Phase 1b trials anticipated in the second half of next year.
Headwinds
- No specific negative guidance was provided in the report.
- The report focuses on upcoming milestones and trial results.
- Forward-looking statements are subject to risks, uncertainties, and assumptions.
- VYNE's ability to obtain additional funding is a risk factor.
- VYNE's ability to comply with regulations is a risk factor.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2024
-1.0%
Avg return
Earnings day
-2.1%
Avg return
5 days after
-10.8%
Avg return
30 days after
52%
17 / 33 earnings
Positive
+23.0%
Q4 2021
Best reaction
-38.4%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.0% | — | — | |
| Q4 2025 | +1.0% | -0.2% | -0.5% | |
| Q2 2025 | +0.6% | -4.3% | -10.6% | |
| Q1 2025 | -2.4% | -20.0% | -28.1% | |
| Q4 2024 | -2.5% | -21.3% | -34.7% | |
| Q3 2024 | +1.0% | -4.2% | -14.4% | |
| Q2 2024 | +8.8% | +8.2% | +7.6% | |
| Q1 2024 | -1.8% | +6.3% | -17.3% | |
| Q4 2023 | -4.7% | -3.4% | +31.8% | |
| Q3 2023 | +1.7% | +11.4% | -23.1% | |
| Q2 2023 | -11.8% | -13.7% | -26.7% | |
| Q1 2023 | +20.9% | +17.9% | -11.9% | |
| Q4 2022 | -14.7% | -21.2% | -11.1% | |
| Q3 2022 | +9.7% | +0.0% | -15.4% | |
| Q2 2022 | +5.3% | +12.5% | -4.6% | |
| Q1 2022 | +5.0% | +8.2% | +27.2% | |
| Q4 2021 | +23.0% | +28.7% | -8.0% | |
| Q3 2021 | -1.5% | -5.9% | +10.3% | |
| Q2 2021 | -38.4% | -42.9% | -45.7% | |
| Q1 2021 | -19.7% | -24.9% | -15.4% | |
| Q4 2020 | -9.7% | -6.5% | -6.5% | |
| Q3 2020 | -2.6% | +0.6% | -1.2% | |
| Q2 2020 | -12.5% | -12.2% | -26.8% | |
| Q1 2020 | -7.2% | -13.3% | +7.2% | |
| Q4 2019 | +5.8% | +42.6% | -9.3% | |
| Q3 2019 | +4.4% | +2.6% | -21.3% | |
| Q2 2019 | -8.7% | -16.4% | +29.8% | |
| Q1 2019 | -1.3% | -2.3% | -4.5% | |
| Q4 2018 | +0.5% | +0.2% | -7.3% | |
| Q3 2018 | +1.7% | +0.0% | -17.8% | |
| Q2 2018 | +3.4% | -2.7% | -5.9% | |
| Q1 2018 | +9.2% | +7.2% | -11.9% | |
| Q4 2017 | +4.8% | +2.9% | -78.1% | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro